MedDataX Logo

MLX/XLX ACR Expandable Lumbar Interbody Implants

NCT ID: NCT04420143

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

109 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-27

Study Completion Date

2020-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety and performance of thoracic and/or lumbar spine surgery using the MLX and XLX ACR interbody implants as measured by reported complications, radiographic outcomes, and clinical patient outcomes. This study is being undertaken to identify possible residual risks and to clarify mid- to long-term clinical performance that may affect the benefit/risk ratios of the MLX and XLX ACR interbody implants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients considered for this study will have previously undergone surgery for their spinal condition according to the standard of care of the practitioner. All patients at a given site with surgeries that meet eligibility requirements will be included in the study and available progress notes, medical records, patient-reported outcomes (PROs), radiographs, and complications will be obtained from the medical records.

The safety and performance of the MLX and XLX ACR interbody implants will be assessed using the following:

1. Complications attributable to the use of the associated interbody implant as noted in surgical summaries, progress notes, and hospital records
2. Neurologic status, symptoms, and subject self-reported clinical outcomes (e.g., pain and disability), as available
3. Radiographic outcome (fusion) and description of device status from plain film radiographs and computed tomography (CT) scan(s), as available

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease Spondylolisthesis Degenerative Scoliosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MLX - Medial Lateral Expandable Lumbar Interbody System

Patients who underwent lumbar interbody fusion with the MLX expandable interbody implant will be included in the MLX - Medial Lateral Expandable Lumbar Interbody System cohort.

No interventions assigned to this group

XLX ACR Interbody System

Patients who underwent lumbar interbody fusion with the XLX ACR expandable interbody implant will be included in the XLX ACR Interbody System cohort.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who were ≥18 years of age at the time of surgery
2. Underwent spine surgery using either MLX or XLX ACR interbody implant (NuVasive, Inc., San Diego, CA) at:

1. One or two adjacent thoracic and/or lumbar levels for degenerative disc disease or degenerative spondylolisthesis, or
2. Any number of thoracic and/or lumbar levels for degenerative scoliosis (defined as \>10º coronal curve)
3. Interbody fusion with autograft and/or allograft (i.e., cancellous and/or corticocancellous allograft bone)
4. NuVasive supplemental internal fixation cleared by the applicable regulatory body for use in the thoracolumbar spine

Exclusion Criteria

1. Use of any bone graft with the associated interbody implant that is not FDA-cleared for use within interbody implants.

Examples of these include:
1. Bone morphogenetic protein (BMP) (e.g., Infuse (Medtronic))
2. Synthetic bone graft extenders (e.g., AttraX (NuVasive), Formagraft (NuVasive), Mastergraft (Medtronic), Vitoss (Stryker), Actifuse (Baxter), nanOss (RTI Surgical), Fibergraft (Prosidyan/Depuy Synthes), ChronOs (Depuy Synthes))
3. Demineralized bone matrices (DBM) regulated as medical devices by the FDA (e.g., Grafton Putty/Gel (Medtronic), DBX (MTF/Depuy Synthes), Accell Evo3 (IsoTis), Propel Putty/Gel (NuVasive))
4. Peptide enhanced bone graft (e.g., iFactor (Cerapedics))
2. Previous lumbar fusion surgery at the currently treated level(s) (adjacent-level surgery is acceptable)
3. Systemic or local infection (latent or active) or signs of local inflammation documented at the time of surgery
4. Patient was involved in active litigation relating to the spine during the surgical/postoperative period (worker's compensation claim is allowed if it is not contested)
5. Inadequate bone stock or bone quality documented at the time of surgery
6. Known sensitivity to materials implanted documented at the time of surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NuVasive

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kyle Malone, MS

Role: STUDY_DIRECTOR

NuVasive

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orthopaedic Specialty Institute

Orange, California, United States

Site Status

Lyerly Neurosurgery

Jacksonville, Florida, United States

Site Status

Carolina NeuroSurgery & Spine Associates

Charlotte, North Carolina, United States

Site Status

OrthoCarolina Research Institute

Charlotte, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NUVA.EXP0120

Identifier Type: -

Identifier Source: org_study_id